TAIPEI, Taiwan – Taipei-based OBI Pharma Inc. has entered into a deal with Merck Sharp & Dohme (MSD) for the development and commercialization in Taiwan of its narrow-spectrum macrocyclic antibiotic Dificid (fidaxomicin), which is used to treat Clostridium difficile-associated diarrhea (CDAD).
TAIPEI, Taiwan – Probably the most anticipated sessions at the recent BioBusiness Asia conference, part of BioTaiwan 2015, were panels featuring advice from partnering executives at firms famous for their external collaboration efforts, who described how a mix of traditional and nontraditional partnering models can bolster early research and maximize innovation.
TAIPEI, Taiwan – Probably the most anticipated sessions at the recent BioBusiness Asia conference, part of BioTaiwan 2015, were panels featuring advice from partnering executives at firms famous for their external collaboration efforts, who described how a mix of traditional and nontraditional partnering models can bolster early research and maximize innovation.
TAIPEI, Taiwan – China's fast-growing health care sector presents excellent opportunities for industry collaboration for overseas companies. And Taiwan, with its existing cultural, language and business ties with China, is particularly well placed to take advantage of those conditions.
TAIPEI, Taiwan – China's fast-growing health care sector presents excellent opportunities for industry collaboration for overseas companies. And Taiwan, with its existing cultural, language and business ties with China, is particularly well placed to take advantage of those conditions.
TAIPEI, Taiwan – Translational science specialist BRIM Biotechnology Inc. has entered a collaboration agreement with Janssen Pharmaceutica N.V., a unit of Johnson & Johnson, for research, development and commercialization of compounds identified by Janssen for dengue fever indications.
TAIPEI, Taiwan – Translational science specialist BRIM Biotechnology Inc. has entered a collaboration agreement with Janssen Pharmaceutica N.V., a unit of Johnson & Johnson, for research, development and commercialization of compounds identified by Janssen for dengue fever indications.
TAIPEI, Taiwan – Pharmaengine Inc. said it submitted a new drug application (NDA) to the TFDA, Taiwan's drug regulatory body, for the liposome version of irinotecan, PEP02, as a second-line treatment for pancreatic cancer patients who have failed gemcitabine therapy.
TAIPEI, Taiwan – Pharmaengine Inc. said it submitted a new drug application (NDA) to the TFDA, Taiwan's drug regulatory body, for the liposome version of irinotecan, PEP02, as a second-line treatment for pancreatic cancer patients who have failed gemcitabine therapy.
